IMUNON CEO Looks Ahead to Key Milestones in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 29 2025
0mins
Should l Buy IMNN?
CEO Stacy Lindborg said in a shareholder letter, in part, "As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data validation, and strategic execution that has significantly strengthened IMUNON's position. Our focus on harnessing the power to activate the body's immune system against cancer has yielded compelling results, bringing us closer to delivering innovative therapies that could transform patient outcomes and create substantial value for you, our shareholders. Very importantly, we believe that we are well positioned for an equally successful 2026...As we enter 2026, IMUNON is poised for key milestones, including continued enrollment in OVATION 3 with interim analyses potentially enabling early stopping and BLA filing in the HRD+ population. We anticipate additional data presentations at major conferences, further translational insights from OVATION 2 tumor samples, and progress on business development initiatives. With Fast Track and Orphan Drug designations in place, we are dedicated to bringing IMNN-001 to patients in need while driving sustainable shareholder value. On behalf of the IMUNON team, thank you for your unwavering support. Together, we are on the cusp of redefining cancer care.'
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMNN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMNN
Wall Street analysts forecast IMNN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.880
Low
12.00
Averages
12.00
High
12.00
Current: 2.880
Low
12.00
Averages
12.00
High
12.00
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Imunon Q4 2025 Earnings Call Highlights
- Survival Rate Improvement: Imunon reported an increase in median overall survival from 11.1 months to 14.7 months in the OVATION 2 trial, indicating significant treatment efficacy improvement that could enhance the company's competitive position in oncology.
- OVATION 3 Execution Progress: The company has enrolled patients at 7 clinical sites for the OVATION 3 trial, with a target of approximately 80 patients to be enrolled within the next 12 months, which could accelerate the timeline for a Biologics License Application (BLA).
- Strong Financial Position: As of December 31, 2025, Imunon reported $8.8 million in cash, and through a diversified financing strategy and cost-saving initiatives, it projects to extend its operating runway into the second half of 2026, ensuring continued R&D efforts.
- Strategic Reorganization: The company implemented a strategic reorganization in February 2026 aimed at reducing nonessential costs and sharpening its operational focus on the OVATION 3 project, which will help improve operational efficiency and optimize resource allocation.
See More
Imunon Reports Improved Survival Rates and Extended Operating Runway
- Survival Rate Improvement: Imunon reported a significant increase in median overall survival from 11.1 months to 14.7 months in the OVATION 2 study, indicating a notable enhancement in treatment efficacy that could strengthen the company's competitive position in the oncology market.
- Extended Operating Runway: The company has successfully optimized its cash usage, extending its operating runway into the second half of 2026, demonstrating effective financial management that supports the ongoing OVATION 3 trial.
- Trial Enrollment Momentum: The OVATION 3 trial is enrolling ahead of schedule, with strong interest from clinical sites and investigators, suggesting market recognition of the treatment and potentially accelerating future clinical development and financing opportunities.
- Exploring Partnership Opportunities: Imunon is exploring non-dilutive partnerships related to its TheraPlas technology platform, which could further extend its financial runway and enhance the company's stability in a challenging capital market environment.
See More
Imunon Reports FY Losses, EPS at -$6.83
- Financial Loss: Imunon's FY GAAP EPS stands at -$6.83, indicating a worsening loss compared to the previous year, which highlights ongoing challenges in profitability that could undermine investor confidence.
- Market Reaction: The reported losses exceeding market expectations may lead to investor concerns regarding the company's future growth prospects, potentially resulting in increased stock price volatility and affecting its financing capabilities.
- Historical Data Comparison: Compared to historical financial data, Imunon's performance shows no signs of improvement, and the continued losses may force the company to reassess its business model and strategic direction to remain competitive in the market.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, Imunon's financial situation has drawn analyst scrutiny, which could impact its market position in the biotechnology sector and further intensify financing and operational pressures.
See More
Imunon Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement: Imunon (IMNN) is set to announce its Q4 earnings on March 30 before the market opens, with a consensus EPS estimate of -$1.82, indicating ongoing challenges in profitability.
- Earnings Performance: Over the past year, IMNN has failed to beat EPS estimates 0% of the time, reflecting a lack of confidence in its earnings potential, which could negatively impact its stock price.
- Revenue Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments; however, this has not alleviated the market's pessimistic outlook on the company's profitability, suggesting analysts remain skeptical about future performance.
- Quantitative Rating Analysis: According to Seeking Alpha's Quant Rating, Imunon's financial performance and market outlook remain poor, potentially exacerbating investor concerns regarding its future growth prospects.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
See More
Imunon Q4 2025 Earnings Call Highlights
- Survival Rate Improvement: Imunon reported an increase in median overall survival from 11.1 months to 14.7 months in the OVATION 2 trial, indicating significant treatment efficacy improvement that could enhance the company's competitive position in oncology.
- OVATION 3 Execution Progress: The company has enrolled patients at 7 clinical sites for the OVATION 3 trial, with a target of approximately 80 patients to be enrolled within the next 12 months, which could accelerate the timeline for a Biologics License Application (BLA).
- Strong Financial Position: As of December 31, 2025, Imunon reported $8.8 million in cash, and through a diversified financing strategy and cost-saving initiatives, it projects to extend its operating runway into the second half of 2026, ensuring continued R&D efforts.
- Strategic Reorganization: The company implemented a strategic reorganization in February 2026 aimed at reducing nonessential costs and sharpening its operational focus on the OVATION 3 project, which will help improve operational efficiency and optimize resource allocation.
See More
Imunon Reports Improved Survival Rates and Extended Operating Runway
- Survival Rate Improvement: Imunon reported a significant increase in median overall survival from 11.1 months to 14.7 months in the OVATION 2 study, indicating a notable enhancement in treatment efficacy that could strengthen the company's competitive position in the oncology market.
- Extended Operating Runway: The company has successfully optimized its cash usage, extending its operating runway into the second half of 2026, demonstrating effective financial management that supports the ongoing OVATION 3 trial.
- Trial Enrollment Momentum: The OVATION 3 trial is enrolling ahead of schedule, with strong interest from clinical sites and investigators, suggesting market recognition of the treatment and potentially accelerating future clinical development and financing opportunities.
- Exploring Partnership Opportunities: Imunon is exploring non-dilutive partnerships related to its TheraPlas technology platform, which could further extend its financial runway and enhance the company's stability in a challenging capital market environment.
See More
Imunon Reports FY Losses, EPS at -$6.83
- Financial Loss: Imunon's FY GAAP EPS stands at -$6.83, indicating a worsening loss compared to the previous year, which highlights ongoing challenges in profitability that could undermine investor confidence.
- Market Reaction: The reported losses exceeding market expectations may lead to investor concerns regarding the company's future growth prospects, potentially resulting in increased stock price volatility and affecting its financing capabilities.
- Historical Data Comparison: Compared to historical financial data, Imunon's performance shows no signs of improvement, and the continued losses may force the company to reassess its business model and strategic direction to remain competitive in the market.
- Analyst Ratings: According to Seeking Alpha's Quant Rating, Imunon's financial situation has drawn analyst scrutiny, which could impact its market position in the biotechnology sector and further intensify financing and operational pressures.
See More
Imunon Scheduled to Announce Q4 Earnings on March 30
- Earnings Announcement: Imunon (IMNN) is set to announce its Q4 earnings on March 30 before the market opens, with a consensus EPS estimate of -$1.82, indicating ongoing challenges in profitability.
- Earnings Performance: Over the past year, IMNN has failed to beat EPS estimates 0% of the time, reflecting a lack of confidence in its earnings potential, which could negatively impact its stock price.
- Revenue Estimate Revisions: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments; however, this has not alleviated the market's pessimistic outlook on the company's profitability, suggesting analysts remain skeptical about future performance.
- Quantitative Rating Analysis: According to Seeking Alpha's Quant Rating, Imunon's financial performance and market outlook remain poor, potentially exacerbating investor concerns regarding its future growth prospects.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
IMUNON Secures $7 Million from Institutional Investor in Direct Stock Offering
- Financing Agreement Reached: IMUNON has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 1,939,114 shares of common stock and associated warrants, with expected gross proceeds of approximately $7 million, enhancing the company's liquidity to support its clinical-stage immunotherapy development.
- Warrant Details: Each share is priced at $3.61, with warrants having an exercise price of $3.482, which will be exercisable immediately and expire in five years, providing the company with additional capital sources to drive future R&D efforts.
- Market Reaction Anticipated: The offering is expected to close on December 31, 2025, and if successful, will help IMUNON maintain compliance with Nasdaq requirements and avoid potential delisting risks, thereby boosting investor confidence.
- Registration Statement Background: The securities are being offered under a Form S-3 registration statement declared effective on May 22, 2024, ensuring compliance and laying the groundwork for future financing activities, demonstrating the company's flexibility and adaptability in capital markets.
See More
